title: Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems.
abstract: OBJECTIVE
  Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disease. Patients are at risk of developing cytopenias or progression to acute myeloid leukemia. Different classifications and prognostic scoring systems have been developed. The aim of this study was to compare the different prognostic scoring systems.
  
  
  METHODS
  One hundred and one patients who were diagnosed with primary MDS in 2003-2011 in a tertiary care university hospital's hematology department were included in the study.
  
  
  RESULTS
  As the International Prognostic Scoring System (IPSS), World Health Organization Classification-Based Prognostic Scoring System (WPSS), MD Anderson Prognostic Scoring System (MPSS), and revised IPSS (IPSS-R) risk categories increased, leukemia-free survival and overall survival decreased (p<0.001). When the IPSS, WPSS, MPSS, and IPSS-R prognostic systems were compared by Cox regression analysis, the WPSS was the best in predicting leukemia-free survival (p<0.001), and the WPSS (p<0.001) and IPSS-R (p=0.037) were better in predicting overall survival.
  
  
  CONCLUSIONS
  All 4 prognostic systems were successful in predicting overall survival and leukemia-free survival (p<0.001). The WPSS was found to be the best predictor for leukemia-free survival, while the WPSS and IPSS-R were found to be the best predictors for overall survival.
authors.affiliation: Hacettepe University Faculty of Medicine, Department of Hematology, Ankara, Turkey, Phone : +90 532 543 05 75, E-mail : ozlenbektas@hotmail.com.
authors.forename: Özlen
authors.initials: Ö
authors.lastname: Bektaş
authors.forename: Ayşegül
authors.initials: A
authors.lastname: Üner
authors.forename: Eylem
authors.initials: E
authors.lastname: Eliaçık
authors.forename: Burak
authors.initials: B
authors.lastname: Uz
authors.forename: Ayşe
authors.initials: A
authors.lastname: Işık
authors.forename: Sezgin
authors.initials: S
authors.lastname: Etgül
authors.forename: Süreyya
authors.initials: S
authors.lastname: Bozkurt
authors.forename: İbrahim Celalettin
authors.initials: İC
authors.lastname: Haznedaroğlu
authors.forename: Hakan
authors.initials: H
authors.lastname: Göker
authors.forename: Nilgün
authors.initials: N
authors.lastname: Sayınalp
authors.forename: Salih
authors.initials: S
authors.lastname: Aksu
authors.forename: Haluk
authors.initials: H
authors.lastname: Demiroğlu
authors.forename: Osman İlhami
authors.initials: Oİ
authors.lastname: Özcebe
authors.forename: Yahya
authors.initials: Y
authors.lastname: Büyükaşık
mesh_terms: D000368:Aged; D001706:Biopsy; D001853:Bone Marrow / Q000473:pathology; D003131:Combined Modality Therapy; D019468:Disease Management; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000175:diagnosis* / Q000401:mortality* / Q000628:therapy; D011379:Prognosis